Avaan Therapeutics, Inc.
An Emerging Biopharmaceutical Company

 

Avaan acquires & accelerates new drug candidates to clinical proof-of-concept in India. The Avaan Model leverages faster clinical validation & capital efficiency to accelerate drug approvals in key markets worldwide.

Management Team

Past Affiliations

Dilip Mehta, MD, PhD

Chairman

SVP Clinical Research Pfizer, Chairman Quintiles India, Hoechst/Aventis, Current Member of FDA's Psychopharmacology Drugs Advisory Committee

Rajnish Mishra, PhD

President & CEO

Founder & CEO Quantros

Al Kraska, PhD

Medical Director

VP Clinical Development, Pfizer

Dave Dresback, PhD

SVP, Pharmaceutical Development

Sr. Director, Drug Delivery & Technology Assessment, Pfizer

 

Strategic Advisory Board

Past Affiliations

Richard Fulmer

Licensing

VP Licensing and Development, Pfizer

David McGibney, MD

Clinical Development

SVP Clinical Development, Pfizer

Alex Giaquinto, PhD

Regulatory

SVP Global Compliance, Schering Plough

Larry Stambaugh

Business Strategy & Finance

Founder & CEO, Maxim Pharmaceuticals

Robert Zerbe, MD

Clinical Development

SVP Clinical Research-Parke Davis, VP-Eli Lilly. Currently, CEO of Quatrx Pharmaceuticals 

For further enquiries, please contact:

Rajnish Mishra, PhD
President & CEO
Avaan Therapeutics, Inc.

Tel. (650) 776 5102
Email: rmishra@avaan.com